19 December 2012

In this issue:

›  Phase 3 clinical trial results for treatment of bacterial vaginosis

› Rapid resolution of symptoms; strong patient acceptability for VivaGel^®

› Taxotere’s anti-cancer effect boosted with Starpharma’s dendrimer technology

› Turning over a new leaf in the world of agrochemicals

› Starpharma wins Janssen Company of the Year Award

Download: Shareholder Update: December 2012 ( pdf file, 1MB)

Read more

8 August 2012

In this issue:

›   VivaGel^® BV trials on track for completion in 2012
›   NDA ready – activities in place to support the BV approval submission
›   Leading the way for Australian innovations
›   Starpharma’s drug delivery program progresses into exciting new areas
›   Crop protection agreement signed with Nufarm
›   Market recognition of Starpharma

Download: Shareholder Update: August 2012 ( pdf file, 1MB)

Read more

16 April 2012

In this issue:

› Starpharma commences pivotal phase 3 VivaGel^® BV treatment trials

› Starpharma continues to build momentum as a leader in the sector

› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model

› Nanobiotechnology to reach $6 billion by 2017

 

Download: Shareholder Update: April 2012 ( pdf file, 1MB)

Read more

20 December 2011

In this issue:

› Starpharma raises $35m to advance pipeline

› Starpharma signs with Ansell for condom coating

› Putting a stop to stubborn BV: The VivaGel^© solution

› Clinical trials for VivaGel^© gather pace

› M&G invests $20 million

› Dendrimers through the eyes of Professor Donald Tomalia

 

Download: Shareholder Update: December 2011 (pdf file, 628kb)

Read more